Users receiving weekly injections saw their weight fall, plateau, and stabilize over the course of a four-year trial—but it’s still unclear how long these effects last after stopping taking the drug.
The findings, published Monday in Nature Medicine , come from a fresh analysis of data from the SELECT trial, which was designed to look at the drug’s effects on cardiovascular health. The trial—a multicenter, double-blind, randomized, placebo-controlled trial—specifically enrolled people with existing cardiovascular disease who also were overweight or obese but did not have diabetes. In all, the trial included 17,604 people from 41 countries.
Researchers behind the SELECT trial, which was funded by Wegovy’s maker, Novo Nordisk, speculate that the trials’ different designs may explain the difference in weight loss. The earlier trial was designed to study weight loss in people who were specifically trying to lose weight and who also tended to be younger than those in the SELECT trial. In addition to semaglutide treatment, the older trial included other lifestyle interventions to aid in weight loss.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wegovy users keep weight off for 4 years: How Wegovy helps the heartPatients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker’s case to insurers and governments to cover the cost of the effective but expensive drug.
Read more »
New Wegovy clinical trial finds surprising benefits that go way beyond weight lossAfter four years of following patients taking Wegovy, the trial revealed how quickly it worked, if patients kept the weight off -- and something else surprising.
Read more »
People on Novo Nordisk's Wegovy maintain weight loss for up to four years, study saysThe results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to cover the costly drug.
Read more »
Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than doubleSales of popular weight loss drug Wegovy more than doubled to 9.38 billion kroner.
Read more »
Wegovy Users Keep Pounds Off for 4 Years: AnalysisPeople with heart problems who took the weight loss drug Wegovy maintained an average weight loss of 10% of their body weight 4 years after starting the drug, according to newly released study results.
Read more »
Cognitive factors may influence attrition, weight loss, and weight maintenance.Specific cognitive factors are associated with attrition, weight loss, and maintenance, but are not usually addressed by the treatment of obesity
Read more »